Market Overview

Shares of Myriad Genetics Move Lower as Co. Reports Launch of myRisk Hereditary Cancer Panel

Share:
Related MYGN
Increased Confidence Earns Myriad Genetics An Upgrade
Benzinga's Top Upgrades, Downgrades For August 18, 2017
EndoPredict® Receives Positive Coverage Decisions From Medicare and Anthem (GuruFocus)

Myriad Genetics, Inc. (Nasdaq: MYGN) announced today that it has launched myRisk Hereditary Cancer, a new multi-gene diagnostic test that will provide increased sensitivity by analyzing 25 genes associated with eight major cancers including: breast, colorectal, ovarian, endometrial, pancreatic, prostate, gastric and melanoma.

myRisk Hereditary Cancer is being launched in a phased approach beginning with an early-access, clinical-experience program to a limited number of medical and scientific thought leaders followed by an expanded access program later in the year. The Company will present extensive clinical validity data for myRisk Hereditary Cancer at The Collaborative Group of the Americas on Inherited Colorectal Cancer (CGA) annual meeting in October and the San Antonio Breast Cancer Symposium in December.

The new myRisk Hereditary Cancer test represents the next generation of hereditary cancer testing and will provide healthcare providers with clear and actionable information to improve patient care, regardless of whether the patient receives a positive or negative test result. Each test report will include a genetic test result, a clinical risk and healthcare management tool based on professional society guidelines.

Posted-In: News FDA

 

Related Articles (MYGN)

View Comments and Join the Discussion!